2024
Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases
Zhao J, Ong J, Chia D, Teo M, Tan Q, Ng G, Tan J, Ma H, Ong X, Tay S, Tan P, Sundar R. Abstract 2759: Transcriptional intra-tumoral heterogeneity of putative therapeutic targets in colorectal cancer peritoneal metastases. Cancer Research 2024, 84: 2759-2759. DOI: 10.1158/1538-7445.am2024-2759.Peer-Reviewed Original ResearchColorectal cancer peritoneal metastasesCRC PMPeritoneal metastasisColorectal cancerIntra-tumor heterogeneitySystemic regimensTherapeutic targetAmerican Association for Cancer Research annual meetingsPrognosis of peritoneal metastasisResistant to systemic chemotherapyPlasma-peritoneal barrierOncological surgical resectionColorectal cancer patientsSystemic chemotherapySurgical resectionPalliative surgerySystemic therapyAntineoplastic therapyPotential therapeutic targetExploratory laparotomyTranscoelomic metastasisPoor prognosisFFPE tissue samplesSynchronous PMPoor responseTotal neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
Wang M, Gwee Y, Lin Z, Yong W, Sundar R, Tan H, Choo J, Tan K, Lieske B, Cheong W, Tan T, Tey J, Chee C, Chan G. Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center. Journal Of Clinical Oncology 2024, 42: 39-39. DOI: 10.1200/jco.2024.42.3_suppl.39.Peer-Reviewed Original ResearchLocally advanced rectal cancerTotal neoadjuvant therapyPathological complete responseDisease-free survivalClinical complete responseCircumferential resection marginCycles of XELOXTumor regression gradeCycles of mFOLFOX6Systemic chemotherapyComplete responseR0 resectionRectal cancerRate of clinical complete responseCycles of systemic chemotherapyPathologic complete response rateThreatened circumferential resection marginCircumferential resection margin involvementDisease-free survival ratesWatch-and-wait approachLimitations of retrospective studiesLong-course CRTMedian tumor distanceAdequate organ functionLong-course chemoradiation
2023
Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients.
Lee M, Peng S, Lee A, Wong S, Tay R, Li J, Tariq A, Goh C, Tan Y, Tan B, Teo C, Chan E, Ooi M, Chng W, Chee C, Ho C, Walsh R, Wong M, Su Y, Alexander L, Sethi S, Tan S, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. Annals, Academy Of Medicine, Singapore 2023, 52: 8-16. PMID: 36730801, DOI: 10.47102/annals-acadmedsg.2022302.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 mRNA vaccinesDoses of SARS-CoV-2 mRNA vaccinesMRNA vaccinesCancer patientsThird doseHaematological malignanciesLong-term immunogenicityCompared to patientsRisk of severe diseaseAnti-neoplastic treatmentActive cancer therapyVirus neutralisation assaySARS-CoV-2 infectionSystemic chemotherapyNo patientEarly administrationSeroconversion ratesVaccine immunogenicitySolid tumorsClinical efficacyClinical outcomesSevere infectionsCancer therapyHumoral responseActive treatment
2022
ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases
Chia D, Ang J, Sundar R, Kim G, Shabbir A, So J, Yong W. ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8606-8607. PMID: 36192514, DOI: 10.1245/s10434-022-12102-1.Peer-Reviewed Original ResearchOutcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Goh G, Seet J, Chee C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Teh J, Lwin A, Soon Y, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8597-8605. PMID: 36070113, DOI: 10.1245/s10434-022-11998-z.Peer-Reviewed Original ResearchConceptsGastric cancer peritoneal metastasisIP-PTXConversion surgeryIntraperitoneal paclitaxelMedian OSSystemic chemotherapyPeritoneal metastasisSC groupConversion to negative cytologyResultsThe median OSProgression-free survivalPhase II studyMethodsForty-four patientsIntravenous oxaliplatinMedian PFSOral capecitabineSystemic capecitabineExtraperitoneal metastasesNegative cytologyPeritoneal diseaseOverall survivalPerformance statusPrimary endpointSecondary endpointsIP cohort
2021
Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.
Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Cheng Ean C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Shabbir A, Yong W, So J. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2021, 39: 165-165. DOI: 10.1200/jco.2021.39.3_suppl.165.Peer-Reviewed Original ResearchIP paclitaxelSystemic chemotherapyPeritoneal metastasisConversion surgeryGastric cancerMedian OSSC groupProspective phase 2 trialIP groupProgression-free survivalPhase II studyBaseline performance statusWound-related complicationsStandard-of-careGCPM patientsIntraperitoneal paclitaxelIV oxaliplatinMedian PFSSystemic capecitabineExtraperitoneal metastasesNegative cytologyOverall survivalPerformance statusPrimary endpointSecondary endpoints
2018
Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.
Chan D, Syn N, Neogh C, Phua N, . E, Ho J, Sundar R, Tan C, Ngoi N, Chee C, Shabbir A, So J, Yong W. Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2018, 36: 125-125. DOI: 10.1200/jco.2018.36.4_suppl.125.Peer-Reviewed Original ResearchConversion gastrectomyPeritoneal metastasisGastric cancerIP paclitaxelMedian OSPeritoneal cytologyDay 1Positive peritoneal washing cytologyTreated with 8 cyclesSurvival rateNegative peritoneal cytologyPeritoneal washing cytologyRecurrent gastric adenocarcinomaHand-foot syndromeMedian follow-upOverall survival rateWeek of restTime of reportingMedian no.Tumor perforationSystemic chemotherapyFebrile neutropeniaIncreasing drug concentrationPeritoneal diseasePeritoneal dissemination
2017
Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials.
Sundar R, McVeigh T, Petruckevitch A, Diamantis N, Ang J, Chenard-Poirier M, Collins D, Lim J, Ameratunga M, Khan K, Kaye S, Banerji U, Lopez J, De Bono J, Van Der Graaf W. Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials. Journal Of Clinical Oncology 2017, 35: 10536-10536. DOI: 10.1200/jco.2017.35.15_suppl.10536.Peer-Reviewed Original ResearchPhase I trialAdvanced solid tumorsPhase I studyAYA patientsI trialFamily historySolid tumorsDrug Development UnitClinical outcomesOutcomes of AYA patientsMedian progression free survivalMolecular characterization of tumorsClinical benefit rateProgression free survivalSomatic genetic aberrationsRoyal Marsden HospitalHereditary cancer syndromesClinical outcomes of adolescentsCharacterization of tumorsMedian OSSystemic chemotherapyFree survivalGenetic aberrationsPredictive biomarkersBenefit rate